Evidence map›Paper›PMID 40746728›Full record

ArticleFrontiers in pharmacology2025

Shaping national rare diseases definition in Saudi Arabia: outcome from health ecosystem multisectoral workshop.

Ghada Mohammed Abozaid, Hussain Abdulrahman Al-Omar, Abdulaziz Alrabiah, Hiba Alomary, Amy Jayne McKnight

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ghada Mohammed AbozaidCentre for Public Health, Institute of Clinical Sciences B, Royal Victoria Hospital, Dentistry and Biomedical Sciences, Queen's University Belfast School of Medicine, Belfast, United Kingdom.
Hussain Abdulrahman Al-OmarDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Abdulaziz AlrabiahGeneral Directorate of National Health Policies and Economics, Saudi Health Council, Riyadh, Saudi Arabia.
Hiba AlomaryDepartment of Applied Linguistics, College of Languages, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Amy Jayne McKnightCentre for Public Health, Institute of Clinical Sciences B, Royal Victoria Hospital, Dentistry and Biomedical Sciences, Queen's University Belfast School of Medicine, Belfast, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Rare diseases are characterized by low prevalence, a profound impact on patients, and significant challenges in accessing treatment. In Saudi Arabia, the absence of an official definition hampers policymaking, resource allocation, and orphan drugs accessibility. This study aimed to address this gap by proposing a definition of rare diseases using inputs and views from a Saudi multi-stakeholder workshop. Methods: A 1-day workshop was hosted in collaboration with the Saudi Health Council in Riyadh on 5 June 2023, involving 59 participants from various sectors, including clinicians, policymakers, patient advocates, and industry professionals. Using the Vevox Results: The findings indicated a strong preference (96%) for an integrated definition combining qualitative and quantitative criteria. Key qualitative terms such as "Disease" (62%), "Serious" (53%), and "Disorder" (51%) were favored for their clarity and broad applicability. "Genetic" etiology was preferred by 91% of participants, citing its relevance and data availability. Patient-centered criteria, including "life-threatening" (73%) and "considerable reduction in quality of life" (91%), were emphasized. Economic and resource-focused considerations, such as "Lack of Resources" and "Combined Efforts to Prevent" (each at 60%), reflected key unmet needs in the current healthcare landscape. Among quantitative criteria, "Prevalence" (82%) emerged as the most accepted, aligned with international practices, although opinions were mixed on the inclusion of population size thresholds, underscoring the definitional complexity of defining RDs with both precision and flexibility. Discussion: This study provides a foundational basis and scientific root for defining rare diseases in the Saudi context, addressing key gaps in healthcare policies. By integrating evidence-based, patient-centered, and resource-oriented criteria, the proposed definition supports equitable access, improved patient care, and sustainable innovation, in alignment with Saudi Arabia's Vision 2030 goals. Further refinement with broader stakeholder inputs is essential for the successful integration of Saudi healthcare policies.

Indexed as

criteriadefinitionpolicyrare diseasesregulatoryreimbursementSaudi Arabia

Identifiers

PMID40746728
PMCPMC12312012

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.